Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.

Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2015 Oct;42(8):977-89. doi: 10.1111/apt.13363. Epub 2015 Aug 14.

PMID:
26271358
2.

Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.

Safroneeva E, Vavricka S, Fournier N, Seibold F, Mottet C, Nydegger A, Ezri J, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2015 Sep;42(5):540-8. doi: 10.1111/apt.13307. Epub 2015 Jul 6. Erratum in: Aliment Pharmacol Ther. 2015 Dec;42(11-12):1334.

PMID:
26148503
3.

Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.

Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM; Swiss Inflammatory Bowel Diseases Cohort Study Group.

Scand J Gastroenterol. 2014 Oct;49(10):1207-18. doi: 10.3109/00365521.2014.946082. Epub 2014 Aug 14.

PMID:
25120029
4.

Prevalence and clinical importance of mesenteric venous thrombosis in the Swiss Inflammatory Bowel Disease Cohort.

Violi NV, Schoepfer AM, Fournier N, Guiu B, Bize P, Denys A; Swiss Inflammatory Bowel Disease Cohort Study Group.

AJR Am J Roentgenol. 2014 Jul;203(1):62-9. doi: 10.2214/AJR.13.12447. Erratum in: AJR Am J Roentgenol. 2014 Aug;203(2):463.

PMID:
24951196
5.

Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.

Höland K, Boller D, Hagel C, Dolski S, Treszl A, Pardo OE, Cwiek P, Salm F, Leni Z, Shepherd PR, Styp-Rekowska B, Djonov V, von Bueren AO, Frei K, Arcaro A.

PLoS One. 2014 Apr 9;9(4):e94132. doi: 10.1371/journal.pone.0094132. eCollection 2014.

6.

Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.

Schaffer T, Schoepfer AM, Seibold F; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2014 Sep;8(9):1125-32. doi: 10.1016/j.crohns.2014.02.014. Epub 2014 Mar 11.

PMID:
24636141
7.

Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate.

Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR; IBD Cohort Study Group.

Am J Gastroenterol. 2013 Nov;108(11):1744-53; quiz 1754. doi: 10.1038/ajg.2013.248. Epub 2013 Aug 27.

PMID:
23978953
8.

Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study.

Sulz MC, Siebert U, Arvandi M, Gothe RM, Wurm J, von Känel R, Vavricka SR, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):790-7. doi: 10.1097/MEG.0b013e32836019b9.

PMID:
23571609
9.

Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study.

Siebert U, Wurm J, Gothe RM, Arvandi M, Vavricka SR, von Känel R, Begré S, Sulz MC, Meyenberger C, Sagmeister M; Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):847-55. doi: 10.1097/MIB.0b013e31827f278e.

PMID:
23446333
10.

Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours.

Boller D, Doepfner KT, De Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, Depledge P, Robson A, Saghir N, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Fattet S, Delattre O, Schweri-Olac A, Höland K, Grotzer MA, Frei K, Spertini O, Waterfield MD, Arcaro A.

Anticancer Res. 2012 Aug;32(8):3015-27.

PMID:
22843869
11.

Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease.

Eloranta JJ, Wenger C, Mwinyi J, Hiller C, Gubler C, Vavricka SR, Fried M, Kullak-Ublick GA; Swiss IBD Cohort Study Group.

Pharmacogenet Genomics. 2011 Sep;21(9):559-64. doi: 10.1097/FPC.0b013e328348f70c.

PMID:
21832969
12.

Epidemiology of inflammatory bowel disease: Is there a shift towards onset at a younger age?

Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V; Swiss IBD Cohort Study Group.

J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):141-4. doi: 10.1097/MPG.0b013e318218be35.

PMID:
21788753
13.

Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals.

Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C; Swiss IBD Cohort Study.

J Crohns Colitis. 2010 Dec;4(6):642-8. doi: 10.1016/j.crohns.2010.07.008. Epub 2010 Aug 12.

PMID:
21122574
14.

Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness.

Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F; Swiss IBD Cohort Study Group.

Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1352-7. Erratum in: Eur J Gastroenterol Hepatol. 2011 Mar;23(3):294. Tempia-Caliera, Michela [corrected to Schäppi, Michela].

PMID:
20964261
15.

Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort.

Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2010 Oct;32(8):1007-16. doi: 10.1111/j.1365-2036.2010.04434.x. Epub 2010 Aug 18.

16.

Lugol chromoendoscopy combined with brush cytology in patients at risk for esophageal squamous cell carcinoma.

Boller D, Spieler P, Schoenegg R, Neuweiler J, Kradolfer D, Studer R, Grossenbacher R, Zuercher U, Meyenberger C, Borovicka J.

Surg Endosc. 2009 Dec;23(12):2748-54. doi: 10.1007/s00464-009-0489-0. Epub 2009 May 15.

PMID:
19444514
17.

Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.

Boller D, Schramm A, Doepfner KT, Shalaby T, von Bueren AO, Eggert A, Grotzer MA, Arcaro A.

Clin Cancer Res. 2008 Feb 15;14(4):1172-81. doi: 10.1158/1078-0432.CCR-07-0737.

18.

Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.

Doepfner KT, Boller D, Arcaro A.

Crit Rev Oncol Hematol. 2007 Sep;63(3):215-30. Epub 2007 Jul 19. Review.

PMID:
17658267
19.

Novel role for insulin as an autocrine growth factor for malignant brain tumour cells.

Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, Jackson SP, Schoenwaelder SM, Delattre O, Grotzer MA, Fischer B.

Biochem J. 2007 Aug 15;406(1):57-66.

20.

Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.

Doepfner KT, Boller D, De Laurentiis A, Guerreiro AS, Marinov M, Arcaro A.

Recent Pat DNA Gene Seq. 2007;1(1):9-23. Review.

PMID:
19075915
Items per page

Supplemental Content

Loading ...
Write to the Help Desk